Olaratumab
- Generic Name
- Olaratumab
- Brand Names
- Lartruvo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1024603-93-7
- Unique Ingredient Identifier
- TT6HN20MVF
- Background
Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratum...
- Indication
用于治疗软组织肉瘤。
- Associated Conditions
- Soft Tissue Sarcoma
- Associated Therapies
- -
Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT03994627
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Kaiser Permanente West Los Angeles, Los Angeles, California, United States
🇺🇸Ironwood Cancer & Research Centers, Glendale, Arizona, United States
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
- Conditions
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2020-07-15
- Target Recruit Count
- 2
- Registration Number
- NCT03698227
- Locations
- 🇩🇪
Medizinische Fakultät Carl Gustav Carus Medizinische Klinik I Internistische Onkologie, Dresden, Germany
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Helios Klinikum Berlin-Buch Klinik für Onkologie und Palliativmedizin, Berlin, Germany
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- University of Miami
- Registration Number
- NCT03437070
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT03283696
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
🇩🇪Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 41
- Registration Number
- NCT03126591
- Locations
- 🇫🇷
Gustave Roussy, Villejuif Cedex, France
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇧🇪Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 184
- Registration Number
- NCT03086369
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 51
- Registration Number
- NCT02783599
- Locations
- 🇺🇸
Moffitt Cancer Center & Research Inst, Tampa, Florida, United States
🇬🇧For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
🇺🇸Kansas City Cancer Center, Overland Park, Kansas, United States
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT02677116
- Locations
- 🇺🇸
St Jude Childrens Research Hospital, Memphis, Tennessee, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Childrens Hospital of Los Angeles, Los Angeles, California, United States
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 310
- Registration Number
- NCT02659020
- Locations
- 🇺🇸
Georgia Cancer Specialists PC, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 509
- Registration Number
- NCT02451943
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Georgia Cancer Specialists PC, Atlanta, Georgia, United States
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.